1-8 of 8
Mark Frattini
Close
Sort by
Journal Articles

Molecular Characterization of Clinical Response and Relapse in Patients with IDH1 -Mutant Newly Diagnosed Acute Myeloid Leukemia Treated with Ivosidenib and Azacitidine

Scott R. Daigle, MS, Sung Choe, PhD, Courtney D. DiNardo, MD MSCE, Anthony S. Stein, MD, Eytan M. Stein, MD, Amir T. Fathi, MD, Olga Frankfurt, MD, Andre C. Schuh, Hartmut Döhner, MD, Giovanni Martinelli, MD, Prapti A. Patel, MD, Emmanuel Raffoux, MD, Peter Tan, MBBS, Amer M. Zeidan, MBBS, MHS, Stephane De Botton, Richard M. Stone, MD, Mark Frattini, MD, Aleksandra Franovic, PhD, Emily Xu, PhD, Thomas Winkler, MD, Bin Wu, PhD, Paresh Vyas, MRCP, FRCP, FRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 49–51.
https://doi.org/10.1182/blood-2020-136922
Published: 2020
Journal Articles

A Phase 1b Study of Venetoclax (ABT-199/GDC-0199) in Combination with Decitabine or Azacitidine in Treatment-Naive Patients with Acute Myelogenous Leukemia Who Are ≥ to 65 Years and Not Eligible for Standard Induction Therapy

Courtney DiNardo, MD, Daniel Pollyea, MD MS, Keith Pratz, MD, Michael J. Thirman, MD, Anthony Letai, MD PhD, Mark Frattini, MD PhD, Brian Jonas, MDPhD, Joel Leverson, PhD, Ming Zhu, PhD, Martin Dunbar, DrPH, Nancy Falotico, Rachel Kirby, BA, Suresh Agarwal, PhD, Mack Mabry, MD, Jalaja Potluri, MD, Rod A. Humerickhouse, MD PhD, Hagop M. Kantarjian, MD, Marina Konopleva, MD PhD
Journal: Blood
Blood (2015) 126 (23): 327.
https://doi.org/10.1182/blood.V126.23.327.327
Published: 2015
Journal Articles

Terminal myeloid differentiation in vivo is induced by FLT3 inhibition in FLT3/ITD AML

Amy Sexauer, Alexander Perl, Xiaochuan Yang, Michael Borowitz, Christopher Gocke, Trivikram Rajkhowa, Christian Thiede, Mark Frattini, Grant E. Nybakken, Keith Pratz, Judith Karp, B. Douglas Smith, Mark Levis
Journal: Blood
Blood (2012) 120 (20): 4205–4214.
https://doi.org/10.1182/blood-2012-01-402545
Published: 2012
Includes: Supplemental data
Journal Articles

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

Clinical Trials & Observations
Renier J. Brentjens, Isabelle Rivière, Jae H. Park, Marco L. Davila, Xiuyan Wang, Jolanta Stefanski, Clare Taylor, Raymond Yeh, Shirley Bartido, Oriana Borquez-Ojeda, Malgorzata Olszewska, Yvette Bernal, Hollie Pegram, Mark Przybylowski, Daniel Hollyman, Yelena Usachenko, Domenick Pirraglia, James Hosey, Elmer Santos, Elizabeth Halton, Peter Maslak, David Scheinberg, Joseph Jurcic, Mark Heaney, Glenn Heller, Mark Frattini, Michel Sadelain
Journal: Blood
Blood (2011) 118 (18): 4817–4828.
https://doi.org/10.1182/blood-2011-04-348540
Published: 2011
Includes: Supplemental data
Journal Articles

A Phase I Study of the Potent Hsp90 Inhibitor STA-9090 Administered Twice Weekly In Subjects with Hematologic Malignancies

Swaminathan Padmanabhan, MBBS, MD, Kevin R Kelly, MD, Mark Heaney, MD, PhD, Stephanie Hodges, Suzanne Chanel, RN, Mark Frattini, MD, Ronan Swords, MD, MRCPI, FRCPath, Robert Bradley, Florentina Teofilovici, MD, MS, Daniel J DeAngelo, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 2898.
https://doi.org/10.1182/blood.V116.21.2898.2898
Published: 2010
Journal Articles

High Mitochondrial Membrane Potential Identifies Patients with Myeloproliferative Neoplasms with a More Aggressive Natural History

Jeffrey R Gardner, MBA, Omar Abdel-Wahab, Mark Frattini, MD, Joseph G Jurcic, MD, Kristina Knapp, Todd L. Rosenblat, MD, MS, Gerald A. Soff, MD, Ross Levine, MD, Mark Heaney, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 1992.
https://doi.org/10.1182/blood.V116.21.1992.1992
Published: 2010
Journal Articles

Characteristic Proinflammatory Serum Cytokine Profiles In Patients with B-Cell Chronic Lymphocytic Leukemia

James J. Harding, MD, Raymond Yeh, PhD, Yan Nikhamin, MS, MBA, Mark Frattini, MD, Nicole Lamanna, MD, Joseph G Jurcic, MD, Mark Heaney, MD, PhD, Renier Brentjens, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3595.
https://doi.org/10.1182/blood.V116.21.3595.3595
Published: 2010
Journal Articles

B Cell Aplasia In a Patient with Relapsed B Cell Acute Lymphoblastic Leukemia Following Re-Induction and Consolidation with Autologous T Cells Genetically Targeted to the CD19 Antigen

Marco L Davila, MD, PhD, Clare Taylor, MSc, Xiuyan Wang, PhD, Jolanta Stefanski, Malgorzata Olszewska, Shirley Bartido, PhD, Mark Frattini, MD, Michel Sadelain, MD, PhD, Isabelle Rivière, PhD, Renier J. Brentjens, MD, PhD
Journal: Blood
Blood (2010) 116 (21): 3268.
https://doi.org/10.1182/blood.V116.21.3268.3268
Published: 2010